Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone

What Was Tested

This randomized controlled trial paper looks at Somatostatin and Lanreotide.

This complication is often severe enough to warrant hospital readmission and may result in renal failure.

Who Took Part

Patients with an ileostomy output ≥ 1.5 l/24 hours were included in this prospective, open, multicentre randomized trial.

Patients were randomly allocated between treatment arms with either lanreotide (LAN) and antidiarrhoeal treatments (TAD) (LAN-TAD group) or antidiarrhoeal treatments only (TADS group).

How the Study Was Run

In design terms this was a randomized and multicenter study.

Because people in this Somatostatin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Running at several centres spread the Somatostatin study over different clinics and patient groups.

The timeline in the abstract includes 72 days.

The primary outcome was ileostomy output after 72 days.

The secondary endpoints were ileostomy output during the first 6 days, blood urea and creatinine values, hospital length of stay and serious adverse events.

What Was Measured

PubMed files the paper under topics including Antidiarrheals, Ileostomy, Peptides, Cyclic and Somatostatin.

The authors tagged it with the keywords Somatostatin analogues, dehydration, high-output stoma and lanreotide.

What This Means in Plain Language

The paper is a randomized and multicenter study of Somatostatin and Lanreotide over 72 days.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Journal of investigative surgery : the official journal of the Academy of Surgical Research), a journal based in United States.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.